AlphaMadera
KalVista Pharmaceuticals, Inc. (KALV)
$27.00
+0.00 (+0.00%)Delayed quote.
Price history
Daily close- Start
- $10.89
- Latest close
- $27.00
- Period change
- +147.93%
- Period low
- $10.89
- Period high
- $27.00
Key metrics
- Market cap
- $1.44B
- Volume
- 4.26M
- Average volume
- 3.54M
- 52-week range
- —
- Beta
- -0.29
- Last dividend
- —
- EPS (TTM)
- -$3.23
- P/E ratio
- -5.00
- Revenue (TTM)
- $73.62M
- Net income (TTM)
- -$164.29M
- Total assets
- $335.38M
- Total debt
- $284.21M
- Cash and equivalents
- $229.34M
Key financials (trailing twelve months).
Company profile
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- CEO
- Benjamin L. Palleiko
- Employees
- 275
- Headquarters
- Framingham, MA, US
- IPO date
- 2015-04-09
- Website
- https://www.kalvista.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2026Dec 31, 2025 | FY2025Apr 30, 2025 | FY2024Apr 30, 2024 |
|---|---|---|---|
| Revenue | $73.62M | $0 | $0 |
| Gross profit | $67.54M | $0 | -$86.17M |
| Operating income | -$171.84M | -$188.00M | -$140.44M |
| EBITDA | -$150.62M | -$173.33M | -$134.28M |
| Net income | -$164.29M | -$183.44M | -$126.64M |
| Diluted EPS | -$3.23 | -$3.69 | -$3.44 |
| Metric | FY2026Dec 31, 2025 | FY2025Apr 30, 2025 | FY2024Apr 30, 2024 |
|---|---|---|---|
| Cash and equivalents | $229.34M | $98.64M | $31.79M |
| Total assets | $335.38M | $250.77M | $235.40M |
| Total liabilities | $338.09M | $155.38M | $28.82M |
| Total debt | $151.57M | $6.31M | $7.32M |
| Shareholders’ equity | -$2.71M | $95.39M | $206.58M |
| Metric | FY2026Dec 31, 2025 | FY2025Apr 30, 2025 | FY2024Apr 30, 2024 |
|---|---|---|---|
| Operating cash flow | -$81.62M | -$152.91M | -$89.23M |
| Capital expenditure | -$1.71M | -$434.0K | -$443.0K |
| Free cash flow | -$83.33M | -$153.34M | -$89.67M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Mar 31, 2026 | Q4 2026Dec 31, 2025 | Q2 2026Oct 31, 2025 | Q1 2026Jul 31, 2025 | Q4 2025Apr 30, 2025 | Q3 2025Jan 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $59.92M | $40.86M | $13.69M | $1.43M | $0 | $0 |
| Gross profit | $55.95M | $37.42M | $12.46M | $836.0K | -$15.89M | $0 |
| Operating income | -$11.51M | -$23.44M | -$46.05M | -$59.01M | -$55.03M | -$42.94M |
| EBITDA | -$3.24M | -$17.55M | -$42.34M | -$54.16M | -$49.88M | -$41.19M |
| Net income | -$5.37M | -$23.49M | -$49.48M | -$60.10M | -$52.23M | -$48.51M |
| Diluted EPS | -$0.11 | -$1.08 | -$0.92 | -$1.12 | -$1.05 | -$0.92 |
| Metric | Q3 2026Mar 31, 2026 | Q4 2026Dec 31, 2025 | Q2 2026Oct 31, 2025 | Q1 2026Jul 31, 2025 | Q4 2025Apr 30, 2025 | Q3 2025Jan 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $229.34M | $229.34M | $243.50M | $124.30M | $98.64M | $167.29M |
| Total assets | $335.38M | $335.38M | $339.93M | $215.50M | $250.77M | $275.99M |
| Total liabilities | $338.09M | $338.09M | $322.93M | $174.72M | $155.38M | $130.87M |
| Total debt | $284.21M | $151.57M | $149.59M | $6.14M | $6.31M | $5.78M |
| Shareholders’ equity | -$2.71M | -$2.71M | $17.00M | $40.79M | $95.39M | $145.13M |
| Metric | Q3 2026Mar 31, 2026 | Q4 2026Dec 31, 2025 | Q2 2026Oct 31, 2025 | Q1 2026Jul 31, 2025 | Q4 2025Apr 30, 2025 | Q3 2025Jan 31, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $45.36M | -$14.46M | -$32.68M | -$54.50M | -$40.36M | -$32.68M |
| Capital expenditure | $156.0K | -$121.0K | -$24.0K | -$290.0K | $350.0K | -$127.0K |
| Free cash flow | $45.52M | -$14.58M | -$32.70M | -$54.79M | -$40.01M | -$32.81M |